Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
384
Recruiting Now
384
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT05732103 Phase 1, Phase 2
Recruiting
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk...
Condition
Acute Myeloid Leukemia
Enrollment
225 pts
Location
United States
Sponsor
Chordia Therapeutics, Inc.
NCT04959903 Phase 1, Phase 2
Recruiting
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematologic...
Condition
Hematological Malignancies
Enrollment
36 pts
Location
United States
Sponsor
Smart Immune SAS
NCT07011186 Phase 1, Phase 2
Recruiting
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Trea...
Condition
Myeloid Malignancy
Enrollment
138 pts
Location
China
Sponsor
Chia Tai Tianqing Pharmaceutic
NCT06253494 Phase 1, Phase 2
Recruiting
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 ...
Condition
Endometrial Cancer
Enrollment
60 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT05000294 Phase 1, Phase 2
Recruiting
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Condition
Bile Duct Cancer
Enrollment
29 pts
Location
United States
Sponsor
University of Florida
NCT07186842 Phase 1, Phase 2
Recruiting
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentia...
Condition
Advanced Solid Cancers
Enrollment
245 pts
Location
United States, Australia, Germany
Sponsor
BioNTech SE
NCT04199741 Phase 1, Phase 2
Recruiting
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Condition
Small Cell Lung Cancer
Enrollment
105 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
NCT06809517 Phase 1, Phase 2
Recruiting
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Met...
Condition
Leptomeningeal Metastasis
Enrollment
34 pts
Location
China
Sponsor
Guangzhou Medical University
NCT06549946 Phase 1, Phase 2
Recruiting
Ixovex-1 Single Agent and Combination Therapy
Condition
Solid Tumor
Enrollment
18 pts
Location
United Kingdom
Sponsor
Psivac Ltd
NCT07397338 Phase 1, Phase 2
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Sol...
Condition
Advanced Solid Tumors
Enrollment
370 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
NCT06327100 Phase 1, Phase 2
Recruiting
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis...
Condition
Primary Myelofibrosis
Enrollment
33 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT07421700 Phase 1, Phase 2
Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With...
Condition
Urothelial Cancer
Enrollment
132 pts
Location
United States, Australia, China
Sponsor
Pfizer
NCT07464132 Phase 1, Phase 2
Recruiting
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Prote...
Condition
Tumor
Enrollment
30 pts
Location
China
Sponsor
Peking Union Medical College H
NCT04396899 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human My...
Condition
Heart Failure
Enrollment
53 pts
Location
Germany
Sponsor
University Medical Center Goet
NCT04771130 Phase 1, Phase 2
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
Condition
Acute Myeloid Leukemia
Enrollment
260 pts
Location
United States, Australia, China
Sponsor
BeOne Medicines
NCT07818018 Phase 1, Phase 2
Recruiting
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junc...
Condition
Esophageal Cancer
Enrollment
30 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
NCT07657390 Phase 1, Phase 2
Recruiting
Prospective Randomized Controlled Clinical Study of Acupoint Application With Gu...
Condition
Cancer Pains
Enrollment
198 pts
Location
China
Sponsor
Cancer Institute and Hospital,
NCT07288580 Phase 1, Phase 2
Recruiting
A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF ...
Condition
Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Enrollment
30 pts
Location
China
Sponsor
Shanghai Euhearing Therapeutic
NCT06626789 Phase 1, Phase 2
Recruiting
Brain Signal Training to Enhance Affect Down-regulation
Condition
Borderline Personality Disorder
Enrollment
164 pts
Location
Germany
Sponsor
Central Institute of Mental He
NCT01891318 Phase 1, Phase 2
Recruiting
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
Condition
Tumors Metastatic to Brain
Enrollment
36 pts
Location
United States
Sponsor
Case Comprehensive Cancer Cent
NCT06619990 Phase 1, Phase 2
Recruiting
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Coliti...
Condition
Ulcerative Colitis (UC)
Enrollment
270 pts
Location
United States, Argentina, Australia
Sponsor
Xencor, Inc.
NCT07204574 Phase 1, Phase 2
Recruiting
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Saf...
Condition
CRC
Enrollment
40 pts
Location
Taiwan
Sponsor
Chang Gung Memorial Hospital
NCT07602855 Phase 1, Phase 2
Recruiting
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants ...
Condition
Neoplasms, Lung
Enrollment
184 pts
Location
United States, Japan
Sponsor
GlaxoSmithKline
NCT01799538 Phase 1, Phase 2
Recruiting
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Condition
Lymphangioleiomyomatosis
Enrollment
100 pts
Location
United States
Sponsor
National Heart, Lung, and Bloo
NCT06726148 Phase 1, Phase 2
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER...
Condition
Advanced HR+/HER2- Breast Cancer
Enrollment
280 pts
Location
United States, Australia, Canada
Sponsor
Novartis Pharmaceuticals
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology